Cordero Alberto M, Quek Simon, Mueller Ralf S
Dermatologia Veterinaria Especializada, Av. Niños Heroes 1665, Guadalajara, Jalisco, 44190, Mexico.
Mount Pleasant Animal Medical Centre, 105 Clementi Street 12, #01-18/20, Singapur 120105, Gelenggang, 578187, Singapore.
Vet Dermatol. 2018 Apr;29(2):104-e41. doi: 10.1111/vde.12515. Epub 2017 Dec 29.
Generalized demodicosis is a common disease in dogs and doramectin has been reported as a successful treatment. Different treatment protocols using doramectin have not been previously evaluated.
To evaluate whether oral administration of doramectin twice a week is more effective than administration by subcutaneous injection once a week.
Twenty nine privately owned dogs affected with generalized demodicosis.
Dogs randomly received one of two treatments. Sixteen dogs were treated with 600 μg/kg doramectin by subcutaneous injection once a week and 13 dogs received 600 μg/kg doramectin by oral administration twice a week.
The mean age of affected dogs was 2.8 and 2.6 years (P = 0.587) and the mean mite number detected at the initial evaluation was 201 and 287 (P = 0.04), respectively, for each group. The mean time to achieve negative skin scrapings was 13 and 12 weeks, respectively (P = 0.955). Adult-onset demodicosis affected five of 16 and two of 13 dogs, respectively (P = 0.662). The success rate for treatment was 13 of 16 (81%) of dogs receiving subcutaneous injections once a week and 12 of 13 (92%) dogs receiving oral dosaging twice a week. (P = 0.691). Four dogs did not achieve disease remission. In the 12 month follow-up period, one dog that had received the once a week protocol relapsed after eight weeks of treatment withdrawal. Adverse effects were not observed in any dog.
Based on the results of this study, oral administration of doramectin twice a week does not achieve a more rapid resolution of canine generalized demodicosis than administration by subcutaneous injection once a week. The treatment success rate was the same for both protocols.
全身性蠕形螨病是犬类常见疾病，多拉菌素已被报道为一种成功的治疗药物。此前尚未对使用多拉菌素的不同治疗方案进行评估。
评估每周口服两次多拉菌素是否比每周皮下注射一次更有效。
29只患有全身性蠕形螨病的私人饲养犬。
犬只随机接受两种治疗中的一种。16只犬每周皮下注射600μg/kg多拉菌素，13只犬每周口服两次600μg/kg多拉菌素。
每组患犬的平均年龄分别为2.8岁和2.6岁（P = 0.587），初次评估时检测到的平均螨数分别为201只和287只（P = 0.04）。皮肤刮片转阴的平均时间分别为13周和12周（P = 0.955）。成年犬蠕形螨病分别影响了16只犬中的5只和13只犬中的2只（P = 0.662）。每周皮下注射一次的16只犬中有13只（81%）治疗成功，每周口服两次的13只犬中有12只（92%）治疗成功（P = 0.691）。4只犬未实现疾病缓解。在12个月的随访期内，接受每周一次治疗方案的1只犬在停药8周后复发。未在任何犬只中观察到不良反应。
基于本研究结果，每周口服两次多拉菌素在治疗犬全身性蠕形螨病方面并不比每周皮下注射一次能更快地解决问题。两种治疗方案的治疗成功率相同。
